Loading company…
Nanjing biotech developing therapeutics for oncology, cardiovascular and inflammatory diseases, including clinical-stage IT-00420.
Based in Nanjing, China and founded in 2016 by Frank Wu, Nanjing TransThera Biosciences focuses on therapies for oncology, cardiovascular and inflammatory diseases. Its clinical-stage kinase inhibitor IT-00420 targets tumor cells and the tumor microenvironment. Other pipeline products include IT-00434 for gastrointestinal tumors, IT-01688 for IBD, TT-00920 for heart failure and TT-01025 for NASH. In July 2021 the company raised USD 100 million in Series D funding co-led by new investors CCT Fund Management and CPE Funds Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in